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Abstract
Oxidative stress occurs in brains of Alzheimer’s disease (AD) patients. A major question in AD research is whether the
oxidative stress is just secondary to neurodegeneration. To test whether oxidative stress is an inherent property of AD tissues,
the ability of cultured fibroblasts bearing the AD Presenilin-1 246 AlaCGlu mutation to handle reactive oxygen species
(ROS) was compared to controls. Although ROS in cells from AD subjects were only slightly less than cells from controls
under basal conditions (310%) or after exposure to H2O2 (316%), treatment with antioxidants revealed clear differences.
Pretreatment with DMSO, a hydroxyl radical scavenger, reduced basal and H2O2-induced ROS levels significantly more in
cells from controls (322%, 322%) than in those from AD subjects (34%, +14%). On the other hand, pretreatment with
Trolox diminished H2O2-induced ROS significantly more in cells from AD (360%) than control subjects (339%). In
summary, cells from AD patients have greater Trolox sensitive ROS and less DMSO sensitive ROS than controls. The results
demonstrate that fibroblasts bearing this PS-1 mutation have altered means of handling oxidative stress and appear useful for
determining the mechanism underlying the altered redox metabolism. ß 2000 Elsevier Science B.V. All rights reserved.
Keywords: Alzheimer’s disease; Fibroblast; Oxidative stress; Reactive oxygen species; Vitamin E; Trolox; Dimethylsulfoxide
1. Introduction
Brains from Alzheimer’s disease (AD) patients
show damage from reactive oxygen species (ROS).
The evidence for such injury includes the presence
of nitrotyrosine [1,2] and of lipid peroxidation prod-
ucts (e.g. hydroxynonenal [3^5] and acrolein [6]), ac-
cumulation of reactive iron [2,7], and activated mi-
croglia [8,9]. In addition, considerable evidence
suggests that the amyloid-L-peptide that accumulates
in plaques can either directly or indirectly enhance
ROS production [10]. Other investigators suggest
that oxidative stress increases accumulation of amy-
loid-L-peptide, a major component of plaques [11].
The involvement of ROS in the pathophysiology of
AD has been reviewed extensively [3,12]. However,
studies of autopsied brain cannot distinguish whether
abnormal oxidative processes are inherent properties
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of AD cells that promote the pathology or are sec-
ondary to neurodegeneration.
Investigations of non-AD cells that have mutant
AD genes transferred into them support the involve-
ment of ROS in the pathophysiology of AD. Cybrid
human neuroblastoma cells that contain mitochon-
drial DNA from AD patients produce more ROS
than cybrids with mtDNA from control subjects
[13]. Mutations in presenilin-1 (PS-1) enhance oxida-
tive stress [14], although the response depends upon
the cell type in which the mutant genes are expressed.
Expression of mutant PS-1 potentiates apoptotic sig-
nals in PC12 cells [15,16], but not in primary cultures
of cortical neurons [17]. These contradictory ¢ndings
demonstrate that the response of the cells to prese-
nilin mutations depends upon the genetic back-
ground of the cell in which PS-1 is expressed and/
or the level of protein expression.
Cultured ¢broblasts from AD patients provide a
cellular system that complements studies of autop-
sied brain and of transfected cells [18,19]. Unlike
autopsied brain, ¢broblasts permit measurement of
dynamic processes in living cells from patients. The
advantage of ¢broblasts compared to transfected
cells is that ¢broblasts allow testing for the e¡ects
of AD-related genetic mutations on dynamic process-
es in cells that have the same genetic background in
which the disease is expressed. The use of ¢broblasts
from family members who do not have the mutation
as controls helps to account for genetic variability.
Furthermore, the mutant protein is expressed at ‘nor-
mal’ pathophysiological concentrations, and expres-
sion is under normal control. AD/control di¡erences
in cultured ¢broblasts re£ect inherent properties of
these cells that are not secondary to neurodegenera-
tion, diet or drugs.
Abnormalities in numerous signaling properties
occur in these cells including changes in calcium dy-
namics, cyclic AMP production and the phosphati-
dylinositide cascade (see reviews [19,20]). Although
growth patterns and time to phase-out do not vary
between ¢broblasts from AD patients, including
those with PS-1 mutations, and control cells [19^
21], the mitotic index after colcemid is diminished
[22]. In addition, changes in amyloid-L-peptide me-
tabolism and mitochondrial function occur (See re-
views [19,20]). The above changes have been reported
in both genetic and non-genetic forms of AD. We
hypothesize that changes in oxidative stress may
underlie these changes. Since the cellular changes
may vary between these forms of AD, the current
studies focused on genetic forms, because this repre-
sents a well-de¢ned population. Our goal is to ¢nd a
converging factor that occurs in ¢broblasts from all
familial AD patients, and to then test those changes
in ¢broblasts from so-called sporadic (i.e. non-genet-
ic forms of AD). In the current study, ¢broblasts
were used to study the e¡ects of the PS-1 246
AlaCGlu mutation on ROS homeostasis.
2. Materials and methods
2.1. Fibroblasts
Human skin ¢broblasts were obtained from Coriell
cell repository (Camden, NJ). The clinical diagnosis,
age and sex of the donors are listed in Table 1. Sev-
eral properties including growth properties and time
to phase-out have been characterized in the cell lines
that were utilized in the current studies. Every e¡ort
was made to use control donors who were from the
AD patient’s family, but who did not have the PS-1
mutation. These are referred to as escapees. As dis-
cussed in Section 1, the genetic background of the
cells in£uences the response to PS-1 mutation, so it is
Table 1
Characteristics of the donors of the ¢broblast lines
Line no. Clinical
diagnosis
Age (years) Sex PS1 mutation
(heterozygous)
4159 AD 52 F Mutant
6840 AD 56 M Mutant
6848 AD 56 F Mutant
8170 AD 56 M Mutant
6844 AD 59 M Mutant
7671 AD 44 M Mutant
7629 AD 54 M Mutant
6838 Escapee 70 F Wild-type
8183 Escapee 65 F Wild-type
6846 Escapee 75 F Wild-type
7657 Escapee 88 F Wild-type
7597 Escapee 38 M Wild-type
8399 Control 19 F Wild-type
7603 Escapee 61 F Wild-type
Line number refers to the cell line numbers from the Coriell
Cell Repository. Escapees are siblings of the AD patients who
do not have the gene defect.
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important to match the cells genetically as closely as
possible. The next priority was to match the subjects
by sex and age. We have not seen di¡erences with sex
or age in the range of donor’s characteristics that are
listed in Table 1 for the variables that di¡er between
AD and control cells.
All cells were cultured by a detailed protocol [21],
and were studied at similar passages (always between
8 and 20). Brie£y, cells were maintained in Dulbec-
co’s modi¢ed Eagle’s medium (DMEM; low glucose,
Gibco, Grand Island, NY) with 10% fetal bovine
serum (FBS, Sigma, St. Louis, MO) in a humidi¢ed
37‡C incubator with 5% CO2. Weekly sub-cultures
were done by trypsinizing and re-seeding the cells
at 104/cm2. For imaging experiments, cells were
seeded at 500 cells/cm2 onto MatTek glass-bottom
Petri dishes (Ashland, MA) 5^6 days before experi-
ments. This protocol allows highly reproducible mea-
sures to be obtained on a variety of cell properties
over the years.
2.2. Con¢rmation of the gene defect
The mutation at PS-1 246 AlaCGlu was veri¢ed
by restriction fragment length polymorphism (RFLP)
in all cell lines [23]. DNA was isolated from ¢bro-
blasts by standard methods [24]. The 103-bp PCR
product was ampli¢ed with primers 849 (5P-AT-
CTCCGGCAGGCATATCT-3P) and 892 (5P-GAA-
ATCACAGCCAAGATGAG-3P) using the following
reaction conditions:100 ng genomic DNA, 1.5 mM
MgCl2, 10 pmol of each primer, 0.5 U Taq DNA
polymerase, 250 mM dNTPs in 10 Wl reaction vol-
ume for 35 cycles at 94‡C for 20 s, 58‡C for 20 s,
72‡C for 20 s). The PCR products were digested with
0.2 U of Dde1 enzyme at 37‡C overnight. The result-
ing restriction fragments were resolved on a 3.5%
MetaPhor agarose gel with ethidium bromide stain-
ing. Dde1 did not restrict the 103-bp wild-type ge-
nomic PCR product. The mutations result in restric-
tion of the 103-bp product into 77- and 26-bp
fragments. The results are shown in Fig. 1.
2.3. Drugs
Trolox (a water-soluble Vitamin E analog) was
purchased from Calbiochem/Novabiochem (San Die-
go, CA). All other reagents were from Sigma (St.
Louis, MO). Since Trolox is not soluble in water at
high concentrations, it was dissolved in DMSO as
200U stocks. The stocks were diluted with the cell
media before adding the compound to the cells. The
¢nal DMSO concentration was 0.5%.
2.4. Fluorescence imaging of ROS generation
ROS species were measured by modi¢cations of
published methods [25]. Fibroblasts were loaded
with 10 WM-6-carboxy-2P,7P-dichlorodihydro£uores-
cein diacetate acetoxymethyl ester (c-H2DCF AM;
Molecular Probes, Eugene, OR) in DMEM+1% bo-
vine serum albumin (BSA)+20 mM HEPES at room
temperature for 60 min. Cells were then rinsed in
balanced salt solution (BSS; mM): NaCl (140),
KCl (5), MgCl2 (1.5), glucose (5), HEPES (10),
CaCl2 (2.5) and incubated at 37‡C for 60 min before
being transferred onto the microscope stage for mea-
surements. A microincubator (Medical Systems,
Long Island, NY) was ¢tted on the microscope stage
to maintain the temperature in the Petri dish at 37‡C.
Excitation light (488 nm; bandpass 3 nm) was ob-
tained with a Photon Technology International
(Monmouth Junction, NJ) monochromator. The
emitted light (535 nm, bandpass 45 nm) passed
through a XF23 dichroic cube (Omega Optical, Brat-
tleboro, VT) and was collected with a Hamamatsu
C2400 8-bit SIT camera. A Photon Technology In-
ternational ImageMaster interface and software con-
Fig. 1. Veri¢cation of PS-1 246 AlaCGlu mutation by RFLP. Nucleotide substitutions in the PS-1 gene were analyzed (Section 2;
[23,24]). The PS-1 246 AlaCGlu mutation results in restriction of the 103-bp PCR product into 77-bp and 26-bp fragments by Dde1;
the arrows indicate the mutation lines.
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trolled the whole system. Composite images (the
average of 64 images taken within 2 s) were obtained
every 10 s. An image of BSS bu¡er in a MatTek Petri
dish was taken as background. Another image of 2 ml
of 100 nM 5-(and 6)-carboxy-dichloro£uorescein
(c-DCF; Molecular Probes; Eugene, OR) in BSS in
the same dish was also taken. This concentration of
c-DCF provided optimal images to be used to correct
for background and uniformity for all the images
taken on that day and intensity di¡erences caused
by machine £uctuation between days. The c-DCF
experiments were done in the dark (i.e. with only a
sodium lamp) to minimize some of the di⁄culties
with these probes [26].
2.5. Fluorescence imaging of intracellular pH (pHi)
pHi was determined by modi¢cation of published
methods [27] to test the possibility that changes in
pHi caused the changes in c-DCF £uorescence. Fi-
broblasts were loaded with 10 nM 2P,7P-bis(2-car-
boxyethyl)-5 (and 6)-carboxy£uorescein, acetoxy-
methyl ester (BCECF-AM; Molecular Probes,
Eugene, OR) in glucose-free BSS (mM): NaCl
(140), KCl (5), MgCl2 (1.5), HEPES (10), CaCl2
(2.5) at room temperature for 60 min. Cells were
then rinsed in the same bu¡er and transferred onto
the microscope stage for measurements. Image pairs
of excitation 493/450 nm (bandpass 3 nm), emission
515 nm (long pass) were taken every 10 s. Measuring
eight standard pH solutions generated a standard
curve (pH 6.0^9.5) in a solution whose ionic compo-
sition mimicked intracellular bu¡er (mM): KCl
(115), NaCl (20), MOPS (10), MgCl2 (1.223),
EGTA (2.223).
2.6. Data processing and statistics
For imaging experiments of ROS generation, each
experimental condition was analyzed on a per cell
basis. Generally, each ¢eld contained about 10 cells.
Unless otherwise indicated in the ¢gure legends, each
measurement was repeated on at least three dishes
each day on 2^3 separate days. Typically, each value
is the mean of measurements from 50^100 cells. This
was used as the value for each cell line. A large range
of cellular responses was observed in each dish, so
that each cell was regarded as an independent mea-
sure. The numbers in the ¢gures are means þ S.E.M.
of that value for all of the indicated cell lines. The
statistical signi¢cance of di¡erences was determined
either by analysis of variance, general linear model,
or with a t-test.
3. Results
3.1. Hydrogen peroxide and the c-DCF signal in cells
A ¢broblast line from a young control was used to
establish the conditions to look at basal ROS pro-
duction and the response to H2O2 under three di¡er-
ent conditions. First, cells were loaded with c-
H2DCF-AM in DMEM containing glucose and oth-
er nutrients, and the response was measured in BSS
with glucose. H2O2 produced a dose-dependent in-
crease in c-DCF £uorescence in the ¢broblasts (Fig.
2). Subsequent experiments used 8.82 mM H2O2 for
treatments because it produced a robust response
without overwhelming the cells within the time frame
of these experiments. In the second paradigm (Fig.
3), cells were loaded with c-H2DCF AM in BSS
Fig. 2. H2O2-induced ROS production in ¢broblasts from a
young control. Cells were loaded with c-H2DCF AM in
DMEM. Cells were then rinsed and incubated with BSS bu¡er
with 5 mM glucose for an additional hour. c-DCF £uorescence
was then measured as described in Section 2. The vertical axis
is the change in relative £uorescence units (RFU) from cDCF
per minute following addition of H2O2 (i.e. the slope of the
RFU signal after the addition of H2O2). Hydrogen peroxide
was mixed into the testing bu¡er during the measurements as
indicated in Section 2. Each value is the mean þ S.E.M. of
27 cells in two dishes measured on two separate days. ***Val-
ues di¡er from control (P6 0.001).
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without glucose and the response was measured in
BSS without glucose. Omitting glucose increases the
Trolox-sensitive oxidative stress because it makes the
cells more dependent upon mitochondrial metabo-
lism. This treatment increased the c-DCF signal
under basal conditions, and exaggerated the slope
after the addition of H2O2 (Fig. 3). In the third treat-
ment, cells were loaded with c-H2DCF AM in BSS
with glucose and the response was measured in BSS
with glucose. This treatment produced a response
that was intermediate between the above two condi-
tions (data not shown). The results show that omis-
sion of substrate from the media increases oxidative
stress under basal conditions and exaggerates ROS
production following the addition of H2O2.
3.2. E¡ects of Trolox on ROS generation in cells with
oxidative stress
To test whether the increase in ROS due to sub-
strate deprivation could be blocked by treatment
with antioxidants, ¢broblasts from a young control
were treated with Trolox. The e¡ects of various Tro-
lox concentrations on the induction of ROS by 8.82
mM H2O2 was determined in normal media. Trolox
produced a concentration-dependent decrease in
ROS formation (% reduction): 20 WM (25%), 200
WM (61%) and 2 mM (84%). Thus, all subsequent
studies were done with 2 mM Trolox. In normal
media, Trolox had little e¡ect on basal values. How-
ever, omission of substrate from the media produced
a Trolox-sensitive increase in ROS. Incubation of
cells in glucose-free BSS during the 2-h premeasure-
ment period increased both the basal and H2O2-in-
duced ROS formation (Fig. 3). Trolox (2 mM) re-
duced the basal ROS levels in the stressed cells so
that they were equivalent to that in normal cells.
Trolox also blocked the H2O2-induced increase in
these stressed cells, so that they were nearly indistin-
guishable from the basal values of normal control
cells (Fig. 3). Thus, Trolox e¡ectively diminished
ROS production in normal and stressed cells, and
the reduction was greater in stressed cells.
3.3. E¡ect of chronic pretreatment with Trolox on
ROS generation in cells with oxidative stress
To test the e¡ects of long-term Trolox pretreat-
ment, ¢broblasts from a young control were incu-
bated with Trolox for 4^5 days (Fig. 4). Both basal
and H2O2-stimulated ROS formation were then de-
termined in the absence of drugs in normal media or
in glucose free BSS. Treatment of cells with Trolox in
normal media for 4^5 days did not change the basal
ROS (Fig. 4A) nor H2O2-induced (Fig. 4B) ROS
generation. However, when tested in glucose-free
bu¡er, long-term Trolox treatment decreased both
the basal ROS and the H2O2-induced ROS genera-
tion by more than 40%. This indicates that the e¡ect
of pretreatment with the antioxidant Trolox was ap-
parent only when the cells were stressed.
3.4. E¡ect of Trolox on c-DCF £uorescence in
a cell-free system
Previous studies suggested that Trolox directly af-
fected DCF £uorescence [28]. Therefore, the direct
interaction of Trolox with c-DCF was examined. c-
DCF (0.1 WM in 2-ml BSS bu¡er) was incubated
with either Trolox (2 mM) in 0.5% DMSO or 0.5%
DMSO alone for 60 min at 37‡C in the same type of
Petri dish as those used for the cell experiments.
Fluorescence at the same settings as for the cell
experiments was measured from ¢ve positions in
three separate dishes. Trolox reduced the relative
Fig. 3. Acute e¡ects of Trolox on ROS generation in normal
and glucose-free media. Fibroblasts from a young control were
loaded with c-H2DCF AM in DMEM and incubated in glu-
cose-containing BSS (normal) or loaded with c-H2DCF AM
and later incubated in glucose-free (Glu-free) BSS. Where indi-
cated, Trolox (2 mM) was included in the dye loading and in-
cubation media. The vertical axis is the relative £uorescence
units (RFU) from cDCF. Where error bars are not present,
they were smaller than the symbols. Each value represents the
mean þ S.E.M. of at least 50 cells measured in three dishes a
day on at least 2 days.
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£uorescence units (RFU; mean þ S.E.M.) by 9.5%
(P6 0.001) from 126 þ 1.1 RFU in the DMSO alone
dish to 114 þ 2.1 RFU. Thus, at the highest concen-
trations that were used in the current experiments,
Trolox slightly, but signi¢cantly, reduced c-DCF
£uorescence in the absence of cells. Most of the Tro-
lox experiments with cells utilized pretreatments. In
those experiments, the extracellular Trolox was ¢rst
washed away, so that the concentrations of Trolox
during monitoring of c-DCF in those experiments
were considerably less than in the cell-free system
described in the current paragraph. Therefore, the
interaction of Trolox with c-DCF was not a concern
in these experiments.
3.5. ROS generation in ¢broblasts bearing the PS-1
246 AlaCGlu mutation
Once conditions were established in the young
control line, ROS generation was compared in ¢bro-
blasts from AD patients and age/genetic-matched
Fig. 5. ROS generation in ¢broblasts from AD patients and
aged controls. Under non-stressed oxidatively stressed condi-
tions (A), the vertical axis is the relative £uorescence units
(RFU). These are arbitrary units. Following addition of H2O2
(B), the change in RFU with time is on the vertical axis. Fibro-
blasts were tested as described in Section 2. Fibroblasts were ei-
ther not treated or treated with DMSO (0.5%) or DMSO+Tro-
lox (2 mM) for 5 days. Subsequent manipulations were done
without drugs. Fibroblasts were loaded with c-H2DCF AM in
DMEM and incubated in glucose-containing BSS. H2O2 was
added as in Section 2. Each value is the mean þ S.E.M. of the
means of seven ¢broblast lines in each group. The value for
each cell line is the mean of at least 50 cells measured in three
dishes a day on at least 2 days. Asterisks denote that bracketed
values di¡er from each other by **P6 0.01 or ***P6 0.001, re-
spectively.
Fig. 4. E¡ects of pretreatment with Trolox on ROS generation
in normal or glucose-free media. (A) In the absence of H2O2
(i.e. basal ROS production), the vertical axis is the relative £uo-
rescence units (RFU). These are arbitrary units. (B) Following
addition of 8.8 mM H2O2, the change in RFU with time is on
the vertical axis. Fibroblasts from a young control subject were
pretreated with either 0.5% DMSO (control) or 2 mM Trolox
dissolved in DMSO for 4^5 days in normal cell culture media.
On the day of the measurements, the c-H2DCF AM loading
and preincubation were performed without Trolox under nor-
mal or glucose-free conditions. Where error bars are not ob-
vious, they were smaller than the borders of the data bars.
Each value represents the mean þ S.E.M. of at least 50 cells
measured in three dishes a day on at least 2 days.
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controls (Fig. 5). Basal ROS generation in AD mu-
tation-bearing ¢broblasts was lower than in the con-
trols (310%), but the di¡erence was not statistically
signi¢cant (Fig. 5A). H2O2 generated less (316%)
ROS in the AD-mutation bearing cells, but the dif-
ference was again not statistically signi¢cant (Fig.
5B). Thus, c-DCF measurements did not show sig-
ni¢cant di¡erences in ROS metabolism between ¢-
broblasts from control and AD subjects under these
conditions. Subsequent experiments with antioxi-
dants do reveal di¡erences between the cells from
appropriately matched controls and AD subjects.
3.6. E¡ect of chronic DMSO on cells from AD
patients and age-matched controls
DMSO is an antioxidant that is particularly e¡ec-
tive against hydroxyl radicals [29,30]. The e¡ect of
DMSO on ROS formation was tested in ¢broblasts
from seven AD and seven control subjects (Fig. 5).
Cells were treated with 0.5% DMSO for 4^5 days.
Cells were loaded with c-H2DCF AM and tested in
the absence of DMSO. DMSO pretreatment had no
signi¢cant e¡ect (34 þ 6%) on the basal ROS pro-
duction in AD cell lines, but reduced basal ROS
production by 22% in control lines from 10.2 þ 1.0
to 7.8 þ 0.6 RFU, (P6 0.001) (Fig. 5A). The percent
changes due to the the drugs are shown in Fig. 6.
The e¡ects of DMSO treatment were signi¢cantly
greater in the controls than in the AD lines
(P6 0.01). DMSO increased the H2O2-induced gen-
eration of ROS in the AD lines (+14%), but de-
creased the ROS production following H2O2 in con-
trol lines (322%) (Fig. 5B). The di¡erence in DMSO
e¡ects between controls and AD cell lines was also
signi¢cant (P = 0.05; Fig. 5B) following H2O2. Thus,
the interaction of DMSO with H2O2 distinguished
AD and control lines and showed that AD lines pro-
duce less DMSO sensitive ROS.
3.7. E¡ects of Trolox on cells from AD patients and
age-matched controls
The long-term e¡ects of Trolox were determined in
¢broblasts from AD patients and age-matched con-
trol subjects. Fig. 5 shows the results of the £uores-
cence measurements. The percent changes due to the
drugs are shown in Fig. 6. Since the Trolox was
solubilized in DMSO, both antioxidants were present
in the Trolox group. The Trolox e¡ects were deter-
mined by comparison to the DMSO group. Both
control and AD ¢broblast lines were exposed to Tro-
lox for 5 days and then tested in the absence of
DMSO/Trolox in normal media or glucose free
BSS. Pretreatment with Trolox reduced basal ROS
in AD (336%, P = 0.0003) and control (328%;
P = 0.0042) lines when tested in normal media. The
reduction was not signi¢cantly greater in the AD
than in control lines (P = 0.11) (Fig. 6A).
Pretreatment with Trolox reduced H2O2-induced
ROS generation in normal media in AD cells
Fig. 6. Changes in ROS with antioxidant treatment. The treat-
ments were as described in Fig. 5. The values indicate the e¡ect
of DMSO or Trolox treatment on cDCF £uorescence expressed
as a percent of the corresponding controls that had no antioxi-
dant present. In A, the percents are based on RFU, while in B,
the percents are based on vRFU/min after the addition of
H2O2. Fibroblasts were either not treated or treated with
DMSO (0.5%) or DMSO+Trolox (2 mM) for 5 days. Measure-
ments were made in the absence of drugs. Asterisks indicate
that the response of the control and AD vary by *P6 0.05 or
**P6 0.01, respectively.
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(360%, P6 0.001) more than in cells from age-
matched controls (339%, P = 0.00065). The Trolox
e¡ect in AD cells was signi¢cantly more than in con-
trol cells (P6 0.05) (Fig. 6B). These experiments on
the e¡ects of Trolox were repeated with four control
and four AD lines in glucose-free BSS. The percen-
tages of ROS reduction in both AD (348% basal,
361% H2O2) and control (336% basal, 345% H2O2)
lines were greater than in normal media. Neverthe-
less, Trolox was still more e¡ective in AD (361%),
than control lines (345%), in reducing H2O2-induced
production of (P6 0.02). Thus, AD lines have great-
er Trolox-sensitive ROS.
3.8. E¡ect of H2O2 on intracellular pH
To test the possibility that H2O2 caused a di¡erent
change in pH in the AD and control ¢broblasts that
a¡ected the c-DCF signal. Intracellular pH (pHi) was
measured under basal condition and after H2O2 in
the AD and control cell lines that showed the great-
est di¡erence in response to H2O2. H2O2 (8.82 mM)
decreased pHi less than 0.2 U in both lines, and it
decreased less in AD than in control lines. Therefore,
neither the increased c-DCF £uorescence with H2O2,
nor the control/AD di¡erences, was a function of
altered intracellular pH. This is not surprising be-
cause the pKa of cDCF is about 4.5 and its £uores-
cence would not be expected to be altered at physio-
logical pH.
4. Discussion
Oxidative stress is well documented in AD brain
[3,31]; however, the markers of oxidative stress in
brain could merely re£ect, rather than cause, the
neurodegeneration. The use of cultured cells permits
testing of the possibility that abnormal ROS metab-
olism is an inherent property of AD cells that is
independent of neurodegeneration, diet or drugs. De-
termining whether changes in oxidative stress are oc-
curring is even di⁄cult in isolated cells. Cells that
have been exposed to low-grade oxidative stress are
able to better withstand subsequent oxidative chal-
lenges [32]. Thus, assessing the underlying cause of
di¡erences in response to oxidative stress is di⁄cult,
but it is possible to test whether two populations of
cells di¡er in their ability to handle an oxidative
stress.
Evidence of increased oxidative stress (i.e. 8-hy-
droxy-2P-deoxyguanosine levels) [33] and increased
sensitivity to irradiation [31] in non-neuronal tissues,
such as lymphocytes, from AD patients suggests that
the AD-related abnormalities in ROS are not simply
a re£ection of neurodegeneration. Fibroblasts com-
plement these other approaches in several ways. They
are non-transformed cells that can be maintained in
culture. Highly reproducible di¡erences can be de-
lineated between cells from control subjects and
AD patients [19,20]. Multiple changes in cell signal-
ing have been reported in ¢broblasts from AD pa-
tients and changes in oxidative processes could
underlie many of these de¢cits [16]. The experiments
in the current study demonstrate that cells bearing a
PS-1 mutations handle oxidative stress di¡erently
than controls.
The precise function of PS-1 is unknown, but pre-
vious studies suggest that PS-1 mutations alter the
ability of cells to handle oxidative stress. Expression
of the human PS-1 L286V mutation in PC12 cells
alters their ability to handle oxidative stress and in-
creases their susceptibility to apoptosis induced by
trophic factor withdrawal, mitochondrial toxins and
amyloid-L-peptide. Furthermore, the antioxidants,
propyl gallate and glutathione, protect cells against
the adverse consequences of the PS-1 mutation
[15,16]. On the other hand, over expression of wild-
type or A246E mutant PS-1 does not enhance apo-
ptosis in postmitotic cortical cells [17]. Thus, the cel-
lular response to mutations in PS-1 depends upon
cell type, and perhaps to the speci¢c mutation in
PS-1. The current studies extend the previous inves-
tigations in two ways. First, the current experiments
use diploid cells, which have normal levels of the PS-
1 protein, and PS-1 expression is under physiological
control. Second, patients’ ¢broblasts have the genetic
background in which the human disease is expressed
as opposed to the genetic background of rats [16] or
mice [17], which were used in published experiments.
The current studies show that with a normal level of
expression of PS-1 protein in the patients’ own ge-
netic background, the cells handle acute oxidative
stress di¡erently than controls.
cDCF is a general measure of ROS that permits
evaluation of how cells respond to oxidative stress.
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The high concentrations of H2O2 that were required
to increase cDCF £uorescence are unlikely to occur
in vivo, but they allow us to examine the cells anti-
oxidant response including that in cellular compart-
ments. The requirement for these high concentrations
likely re£ects the probe used to monitor ROS, the
cell type, and compartmentation. State of the art
£uorescent probes for ROS measurements, such as
cDCF, are relatively insensitive. Our preliminary re-
sults indicate that the concentrations of H2O2 that
do not alter cDCF do alter cell function in particular
compartments in the same manner as they are
changed in cells from AD patients [34]. Every cell
type responds to oxidative stress di¡erently because
they have varying levels of antioxidant processes and
¢broblasts have a high general antioxidant capacity.
In contrast, neurons are particularly sensitive to im-
paired metabolism and oxidative stress [35]. The
ROS that are produced in various compartments in
response to H2O2 appear to be altered by PS-1 mu-
tations. Our preliminary studies show H2O2-induced
alterations in the ER calcium dynamics and mito-
chondrial proteins at H2O2 concentrations that do
not alter cDCF £uorescence [34]. Oxidative stress
has also been linked to a diminished mitotic index
[36], which occurs in AD cells under speci¢c condi-
tions [22].
The inability to identify an AD/control di¡erence
with just H2O2 suggests that only speci¢c aspects of
the antioxidant system are altered. The use of selec-
tive antioxidants allows us to begin to identify the
antioxidant species that may be altered. These con-
centrations of H2O2 produce changes in ER calcium
regulation and mitochondrial calcium that resembles
those in AD ¢broblasts [34], which suggests that
these di¡erences are physiologically important. The
relation of these changes in ¢broblasts to changes in
neurons remains to be determined. However, recent
studies suggest they may have direct relevance.
Changes in calcium that we identi¢ed in ¢broblasts
bearing this PS-1 mutation have now been replicated
in ¢broblasts from transgenic mice bearing the same
mutation. In those mice, the same changes that occur
in ¢broblast occur in cultures of neurons from the
mice [37].
ROS in ¢broblasts from control and AD subjects
were selectively sensitive to di¡erent free radical
scavengers. DMSO reduced basal ROS production
in cell lines from controls, but had no e¡ect in cells
from AD patients. Since DMSO is particularly e¡ec-
tive against hydroxyl radicals [29,30,38], the distin-
guishing e¡ect of DMSO between control and AD
cell lines suggests that they di¡er in their ability to
process hydroxyl radicals. Trolox, a more general
antioxidant that acts on multiple ROS [29,38^42],
was e¡ective in aged control and AD lines under
both basal and H2O2 induced conditions, but was
more e¡ective in AD lines under both conditions.
This selective e¡ect of various antioxidants may ex-
plain why previous studies found AD cells to be
more sensitive than controls to ROS production by
xanthine oxidase and acetaldehyde [43,44] or irradi-
ation [45], but not a¡ected by high oxygen tensions
[46]. Calcium uptake in mitochondria isolated from
¢broblasts is more sensitive to ferrous iron in AD
than in controls [47]. The selective e¡ect of various
ROS may also vary with the AD-related genetic mu-
tation. All previous studies preceded the identi¢ca-
tion of genetically de¢ned AD families.
Considerable data suggest that the endoplasmic
reticulum (ER) and its interaction with oxidative
processes may be particularly important in AD due
to PS-1 mutations. Our previous studies show that
ER calcium pools are altered in ¢broblasts bearing
PS-1 mutations [48]. Our preliminary studies show
that the concentrations of H2O2 used in the current
studies alter ER pools of calcium before they in-
crease the cDCF signal [34]. Transfection studies in-
dicate that PS-1 mutations down-regulate the signal-
ing pathway of the unfolded-protein response in the
ER [49,50]. This reduction promotes accumulation of
unfolded proteins in the ER. The unfolded protein
response includes induction of protein disul¢de iso-
merase [50,51]. The disul¢de isomerase can reduce
the protein disul¢des that result from oxidative
stress. The presence of the disul¢de isomerase sug-
gests that changes in oxidation state may a¡ect these
processes. The thiol-disul¢de group uses glutathione
and glutathione varies between cellular compart-
ments. In the cytosol the GSH to GSSG ratio is
100:1, whereas the ratio in the ER is 2:1. Thus,
the oxidation state of glutathione may make the en-
doplasmic reticulum particularly vulnerable to oxida-
tive changes [51]. The changes in unfolded protein
response to PS-1 mutations has not been examined
in cells with the patients’ own genetic background.
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The current studies demonstrate selective e¡ects of
various antioxidants, and support the use of cellular
systems to develop speci¢c antioxidant treatments.
The hydroxyl radical scavenger DMSO dramatically
quenches the formation of 8-OHdG by ionizing ra-
diation and Fenton reaction, but enhances the for-
mation of UV-induced 8-OHdG, suggesting that
UV-induced 8-OHdG is independent of the genera-
tion of hydroxyl radical [52]. In vascular smooth
muscle cells, di¡erent ROS exert distinct e¡ects on
proliferation and apoptosis. A single exposure to
xanthine oxidase/xanthine produced cell prolifera-
tion, whereas frequent exposures to high levels re-
sulted predominantly in cell death. Administration
of superoxide dismutase and catalase revealed that
superoxide, but not H2O2, was mitogenic, whereas
H2O2 was responsible for cell death. Treatment
with H2O2^Fe(II) alone or in the presence of di¡er-
ent hydroxyl radical scavengers showed that cell
death was mediated by the formation of hydroxyl
radicals [53]. Application of these approaches to ¢-
broblasts should reveal the precise site of the abnor-
mality in redox metabolism in AD.
In the current study, prolonged pretreatment with
Trolox enhanced the ability of ¢broblasts to deal
with increased oxidative stress. The enzymes that
are involved in detoxi¢cation of H2O2 in ¢broblasts
include catalase, glutathione peroxidase, and di¡er-
ent forms of superoxide dismutase. Chronic pretreat-
ment of young controls with Trolox had no e¡ect on
either basal or H2O2-induced ROS formation (Fig.
4). However, pretreatment of these young cells with
Trolox enhanced their ability to handle oxidative
stress due to glucose deprivation. This suggests that
Trolox induces a more ‘reduced state’ in cells, so that
they can handle oxidative insults stress more e¡ec-
tively during stress. Several reports suggest that
treatment with vitamin E can increase the levels of
antioxidant enzymes. Vitamin E increases global
antioxidant capacity of the heart [54] and increases
SOD in kidney [55] and liver [56]. In human ¢bro-
blasts, supplementing with vitamin E increases gluta-
thione peroxidase activity, but decreases SOD [57]. If
the current cells respond in this manner, then the
enhanced antioxidant response after Trolox pretreat-
ment in the stressed controls is due to increased glu-
tathione peroxidase. In summary, pretreatment with
Trolox enhances cellular antioxidant capacity, and
more stressed cells (and cells from AD patients) dem-
onstrate a greater response to Trolox.
5. Conclusions
Although the precise mechanism(s) remain to be
determined, the results demonstrate that an altered
ability to handle oxidative insults stress is an inherent
property of AD cells from this PS-1 kindred. Cul-
tured ¢broblasts may be a useful way to test the
e¡ectiveness of various antioxidants for treating
AD patients.
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